Drug Search Results
More Filters [+]

ANC-501

Alternative Names: anc-501, anc 501, anc501
Latest Update: 2023-06-23
Latest Update Note: Clinical Trial Update

Product Description

ANC-501 is a drug candidate for the treatment of major depressive disorder from Aditum Bio. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05439603)

Mechanisms of Action: V1b Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ANC-501

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ANC501D0005

P2

Active, not recruiting

Depressive Disorder, Major

2023-09-25

Recent News Events